Glyset: Advanced Glycemic Control for Type 2 Diabetes

Glyset

Glyset
Product dosage: 50mg
Package (num)Per pillPriceBuy
30$2.61$78.31 (0%)🛒 Add to cart
60$1.96$156.62 $117.47 (25%)🛒 Add to cart
90
$1.74 Best per pill
$234.94 $156.62 (33%)🛒 Add to cart
Synonyms

Glyset (miglitol) is an alpha-glucosidase inhibitor designed to manage blood glucose levels in adults with type 2 diabetes mellitus. By delaying the digestion of carbohydrates in the small intestine, it reduces postprandial hyperglycemia, offering a targeted mechanism complementary to diet, exercise, and other antidiabetic agents. Its unique mode of action supports more stable daily glucose profiles without stimulating insulin secretion, making it a valuable option for tailored diabetes management strategies in clinical practice.

Features

  • Active ingredient: Miglitol 25mg, 50mg, or 100mg tablets
  • Mechanism: Alpha-glucosidase enzyme inhibition
  • Delays carbohydrate digestion and glucose absorption
  • Administered orally with the first bite of each main meal
  • Not metabolized systemically; excreted unchanged by the kidneys
  • Suitable for monotherapy or combination therapy with other antidiabetic agents

Benefits

  • Reduces postprandial blood glucose spikes effectively
  • Lowers HbA1c levels as part of a comprehensive diabetes management plan
  • Minimizes risk of hypoglycemia when used as monotherapy
  • Does not cause weight gain
  • Compatible with other glucose-lowering medications for synergistic effects
  • Supports long-term glycemic stability without stimulating insulin secretion

Common use

Glyset is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is commonly used both as monotherapy and in combination with sulfonylureas, metformin, or insulin when glycemic targets are not achieved with single-agent therapy. It is particularly beneficial for individuals experiencing significant postprandial glucose excursions.

Dosage and direction

The recommended starting dosage is 25mg taken orally three times daily at the start (with the first bite) of each main meal. The dosage may be increased after 4–8 weeks to 50mg three times daily based on tolerability and glycemic response. For some patients, further titration to 100mg three times daily may be appropriate. Dosage adjustments should be guided by 1-hour postprandial glucose levels or HbA1c measurements. Do not crush or chew tablets; swallow whole with water.

Precautions

  • Use with caution in patients with renal impairment (creatinine clearance <25 mL/min); not recommended in severe renal dysfunction.
  • Not intended for use in type 1 diabetes or for the treatment of diabetic ketoacidosis.
  • Gastrointestinal side effects are common initially; a gradual dose titration may improve tolerability.
  • Monitor liver function periodically during long-term therapy.
  • May reduce serum iron levels; periodic monitoring is advised in susceptible individuals.
  • Inform patients that sucrose or glucose (not table sugar) must be used to correct hypoglycemia, as Glyset delays digestion of complex carbohydrates.

Contraindications

  • Hypersensitivity to miglitol or any component of the formulation.
  • Diabetic ketoacidosis.
  • Inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction.
  • Chronic intestinal diseases associated with marked disorders of digestion or absorption.
  • Conditions that may deteriorate as a result of increased gas formation in the intestine.

Possible side effects

  • Very common (>10%): Flatulence, diarrhea, abdominal pain
  • Common (1–10%): Nausea, dyspepsia, skin rash
  • Uncommon (0.1–1%): Edema, headache, dizziness
  • Rare (<0.1%): Transaminase elevation, reduced serum iron levels
  • Gastrointestinal symptoms often diminish with continued treatment.

Drug interaction

  • May reduce bioavailability of digoxin, ranitidine, and propranolol; monitor levels and adjust dosages if necessary.
  • Concomitant use with intestinal adsorbents (e.g., charcoal) or digestive enzyme preparations (e.g., amylase, pancreatin) may reduce efficacy; avoid concurrent administration.
  • Effects may be additive with other hypoglycemic agents; monitor blood glucose to avoid hypoglycemia.
  • Not expected to interact with cytochrome P450-metabolized drugs.

Missed dose

If a dose is missed, skip it and take the next dose at the regular time with a meal. Do not double the dose to make up for a missed one.

Overdose

Overdose may result in transient increases in flatulence, diarrhea, and abdominal discomfort. Hypoglycemia has not been reported with miglitol monotherapy overdose. In case of suspected overdose, provide supportive care. If hypoglycemia occurs due to combination therapy, administer oral glucose (dextrose) instead of sucrose.

Storage

Store at room temperature (15–30°C/59–86°F) in a dry place. Keep the bottle tightly closed and protect from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient needs and responses may vary.

Reviews

Glyset has been evaluated in multiple clinical trials demonstrating significant reductions in postprandial glucose and HbA1c levels. In a 1-year multicenter study, patients on Glyset 50mg TID showed an average HbA1c reduction of 0.7% compared to placebo. Practitioners appreciate its mechanism-specific action and favorable side effect profile, particularly the low risk of hypoglycemia and weight neutrality. Long-term users often report improved day-to-day glucose stability, though gastrointestinal effects during the initiation phase are commonly noted.

More info: